21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The Role of Carbon Monoxide and Heme Oxygenase in the Prevention of Sickle Cell Disease Vaso-Occlusive Crises

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sickle Cell Disease (SCD) is a painful, lifelong hemoglobinopathy inherited as a missense point mutation in the hemoglobin (Hb) beta-globin gene. This disease has significant impact on quality of life and mortality, thus a substantial medical need exists to reduce the vaso-occlusive crises which underlie the pathophysiology of the disease. The concept that a gaseous molecule may exert biological function has been well known for over one hundred years. Carbon monoxide (CO), although studied in SCD for over 50 years, has recently emerged as a powerful cytoprotective biological response modifier capable of regulating a host of physiologic and therapeutic processes that, at low concentrations, exerts key physiological functions in various models of tissue inflammation and injury. CO is physiologically generated by the metabolism of heme by the heme oxygenase enzymes and is measurable in blood. A substantial amount of preclinical and clinical data with CO have been generated, which provide compelling support for CO as a potential therapeutic in a number of pathological conditions. Data underlying the therapeutic mechanisms of CO, including in SCD, have been generated by a plethora of in vitro and preclinical studies including multiple SCD mouse models. These data show CO to have key signaling impacts on a host of metallo-enzymes as well as key modulating genes that in sum, result in significant anti-inflammatory, anti-oxidant and anti-apoptotic effects as well as vasodilation and anti-adhesion of cells to the endothelium resulting in preservation of vascular flow. CO may also have a role as an anti-polymerization HbS agent. In addition, considerable scientific data in the non-SCD literature provide evidence for a beneficial impact of CO on cerebrovascular complications, suggesting that in SCD, CO could potentially limit these highly problematic neurologic outcomes. Research is needed and hopefully forthcoming, to carefully elucidate the safety and benefits of this potential therapy across the age spectrum of patients impacted by the host of pathophysiological complications of this devastating disease.

          Related collections

          Author and article information

          Contributors
          Journal
          7610369
          422
          Am J Hematol
          Am. J. Hematol.
          American journal of hematology
          0361-8609
          1096-8652
          2 December 2017
          29 April 2017
          June 2017
          10 December 2017
          : 92
          : 6
          : 569-582
          Affiliations
          Hillhurst Biopharmaceuticals, Inc., 2029 Verdugo Blvd., #125 Montrose, CA, 91020; Phone: 818 445 5890
          University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455; Phone: 612 624 2611, Fax: 612 625 6919
          Harvard Medical School; Beth Israel Deaconess Medical Center, 3 Blackfan Circle Center for Life Sciences, #630 Boston, MA 02115; Phone: 617-735-2851
          Children’s Hospital Los Angeles; University of Southern California, 4650 Sunset Boulevard MS #54 Los Angeles, CA 90027; Phone: 323-361-4624
          Children’s Hospital Los Angeles; University of Southern California, 4650 Sunset Boulevard MS#34 Los Angeles, CA 90027; Phone: 323-361-5470
          Hillhurst Biopharmaceuticals, Inc, 2029 Verdugo Blvd., #125 Montrose, CA, 91020, Phone: 818 445 5890
          Hillhurst Biopharmaceuticals, Inc, 2029 Verdugo Blvd., #125 Montrose, CA, 91020; Phone: 818 445 5890
          University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455; Phone: 612 626 3757; Fax: 612 625 6919
          Article
          PMC5723421 PMC5723421 5723421 nihpa923945
          10.1002/ajh.24750
          5723421
          28378932
          a85f1bab-c9e0-4b7c-8180-3783ac4085d0
          History
          Categories
          Article

          Carbon Monoxide Releasing Molecule,Sickle Cell Disease,Carbon Monoxide,vaso-occlusive crisis,heme oxygenase 1

          Comments

          Comment on this article